Saturday 17 October 2026
Export CRDF’s income statement to Excel — free account
Cardiff Oncology, Inc.
CRDF Healthcare Biotechnology
Cardiff Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $593,000.00, down 13.2% from fiscal 2024. In the quarter to June 2026, revenue fell 14.1%, EPS grew 33.3% and free cash flow fell 41.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.90
0.07
−7.22%
Follow CRDF
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
175.03 | 210.91 | 316.73 | 275.54 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.56) | (9.01) | (31.48) | (12.72) | |
P/B ratio |
3.35 | 3.19 | 4.14 | 2.82 | |
Price to Tangible BV |
3.35 | 3.19 | 4.14 | 2.82 | |
EV/Sales |
109.85 | 125.87 | 220.79 | 157.18 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.37) | (1.77) | (3.45) | (1.86) | |
EV/FCF |
(1.36) | (1.76) | (3.45) | (1.86) | |
Quick Ratio |
3.21 | 3.20 | 3.57 | 4.14 | |
Current Ratio |
3.30 | 3.27 | 3.67 | 4.20 | |
Net Debt/EBITDA |
3.60 | 3.58 | 7.38 | 4.99 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
1.27 | 0.99 | 0.83 | 0.96 | |
Capex/Depreciation |
(1.91) | 0.00 | 0.00 | 0.11 | |
Research and Development Expense of Revenue |
5,687.50% | 16,500.00% | 2,088.48% | 6,830.83% | |
Selling, General and Administrative Expense of Revenue |
3,657.69% | 14,941.46% | 1,232.51% | 3,247.50% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
884.62% | 4,048.78% | 518.93% | 1,153.33% | |
Graham Net Nets |
0.28 | 0.30 | 0.23 | 0.34 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(46.15%) | (41.36%) | (24.56%) | (38.35%) | |
Free Cash Flow Yield |
(46.05%) | (33.83%) | (20.21%) | (30.68%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.17) | (0.18) | (0.09) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.17) | (0.18) | (0.09) | (0.16) | |
Cash per Share |
0.50 | 0.67 | 0.87 | 0.91 | |
Shareholders Equity per Share |
0.39 | 0.51 | 0.68 | 0.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.39 | 0.51 | 0.68 | 0.73 | |
Free Cash Flow |
(11.81) | (12.29) | (5.97) | (10.85) | |
Working Capital |
24.80 | 32.88 | 43.73 | 47.10 | |
Capital Expenditures |
(0.04) | — | 0.00 | (0.02) | |
Net Current Asset Value |
24.80 | 32.88 | 43.63 | 46.81 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.42 | 0.00 | 0.00 | 0.15 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.36 | 0.30 | 0.48 | 0.44 | |
Average Payables |
5.00 | 4.55 | 6.45 | 3.54 | |
Average Assets |
56.53 | 66.99 | 79.54 | 63.34 | |
Average Common Equity |
42.57 | 52.79 | 64.17 | 49.09 |
Columns are period end dates